Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.34M | 46.50M | 37.43M | 43.65M | 32.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.34M | 46.50M | 37.43M | 43.65M | 32.61M |
| Cost of Revenue | 8.16M | 8.13M | 5.92M | 8.80M | 2.72M |
| Gross Profit | 49.17M | 38.37M | 31.51M | 34.85M | 29.89M |
| SG&A Expenses | 25.74M | 27.68M | 26.52M | 26.92M | 25.44M |
| Depreciation & Amortization | -- | 9.01M | 9.01M | 9.01M | 9.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.66M | 56.60M | 49.93M | 52.37M | 46.90M |
| Operating Income | 13.68M | -10.10M | -12.51M | -8.73M | -14.29M |
| Income Before Tax | 6.11M | -22.80M | -20.04M | -8.58M | -17.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.11M | -22.80M | -20.04M | -8.58M | -17.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.11M | -22.80M | -20.04M | -8.58M | -17.99M |
| EBIT | 13.68M | -10.10M | -12.51M | -8.73M | -14.29M |
| EBITDA | 13.99M | -754.00K | -3.13M | 685.00K | -4.91M |
| EPS Basic | 0.03 | -0.10 | -0.10 | -0.04 | -0.09 |
| Normalized Basic EPS | 0.02 | -0.05 | -0.06 | -0.03 | -0.05 |
| EPS Diluted | 0.03 | -0.10 | -0.10 | -0.04 | -0.09 |
| Normalized Diluted EPS | 0.02 | -0.05 | -0.06 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 235.50M | 218.70M | 210.35M | 209.71M | 204.96M |
| Average Diluted Shares Outstanding | 241.60M | 218.70M | 210.35M | 209.71M | 204.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |